Please use this identifier to cite or link to this item:
http://dspace.mediu.edu.my:8181/xmlui/handle/123456789/5982| Title: | Global pharmaceutical patents after the Doha Declaration What lies in the future? |
| Keywords: | Doha acces to medicines patents pharmaceuticals |
| Issue Date: | 30-May-2013 |
| Publisher: | AHRB Research Centre for Studies in Intellectual Property and Technology Law |
| Description: | The purpose of this article is to analyse how developments after the Doha Declaration went wrong; how developing countries can best be helped by IPR legislation; and whether such help can be achieved without taking away the incentives for industry to develop medicines. It is submitted that a legal framework maintaining the global protection of IPRs is needed, especially in developed countries, but that such a framework must allow for compulsory licensing in separate, regional generic markets , and must further create effective barriers for (re-)import into other countries than those targeted by the compulsory licence. This proposal would create a large market currently unused, in which pharmaceuticals could be produced and sold more cheaply, while protecting developed countries from importation of generic drugs. This way, compulsory licensing should work as a tool to promote innovation whilst also protecting public health globally. |
| URI: | http://koha.mediu.edu.my:8181/jspui/handle/123456789/5982 |
| Other Identifiers: | http://www.law.ed.ac.uk/ahrb/script-ed/docs/doha.asp http://www.doaj.org/doaj?func=openurl&genre=article&issn=17442567&date=2004&volume=1&issue=1&spage=12 |
| Appears in Collections: | Law and Political Science |
Files in This Item:
There are no files associated with this item.
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.